Strides Pharma Science Ltd - 532531 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 121211 Name of the Signatory :- Manjula RamamurthyDesignation :- Company Secretary and Compliance Officer
Stock picks by Sameet Chavan: Buy Strides Pharma, sell Grasim
We finally witnessed a decisive price and volume breakout from the recent congestion zone in Strides Pharma
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
Net Sales are expected to increase by 31 percent Y-o-Y (down 2.6 percent Q-o-Q) to Rs. 810.3 crore, according to Sharekhan. Strides Pharma Science Ltd - 532531 - Intimation Pursuant To Regulation 31A Of Sebl (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
Ref: Strides' intimation to stock exchanges dated October 1, 2020 regarding reclassification request received from SeQuent Scientific Limited (SeQuent) for reclassification from 'Promoter Group' to 'Public' Category; Strides' intimation to stock exchanges dated October 29, 2020 regarding Board approval for such reclassification; and Strides' intimation to stock exchanges dated March 17, 2021 regarding Members' approval for such reclassification. Further to the above, we wish to inform you that the Company has submitted an application with your office today i.e., on April 12, 2021, seeking your approval for the reclassification of SeQuent Scientific Limited from 'Promoter Group' to 'Public' category under Regulation 31A of SEBI Listing Regulations. Request you to kindly take the same on record and oblige. Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 12, 2021 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Shareholding for the Period Ended March 31, 2021
Strides Pharma Science Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 09, 2021 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Compliance Certificate For The Half Year Ended 31.03.2021
As per the requirement of Regulation 7(3) of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we hereby confirm that the activities in relation to share transfer facility for the period from October 1, 2020 to March 31, 2021 are maintained with the Company's Registrar and Share Transfer Agent, M/s. KFin Technologies Private Limited (Formerly, Karvy Fintech Private Limited), Hyderabad who are registered with SEBI vide registration number INR000000221. Accordingly, the compliance in respect of Regulation 7(2) is ensured. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Board of Directors of the Company in their meeting held today have allotted 20,000 equity shares of face value of Rs. 10/- each to an eligible ex-employee who has exercised his stock options as per the terms of Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to the above, paid-up share capital of the Company has increased from Rs. 89,66,09,640/- consisting of 8,96,60,964 equity shares of Rs. 10/- each to Rs. 89,68,09,640 consisting of 8,96,80,964 equity shares of Rs. 10/- each Request you to take the same on record. Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Ratan Chand